This review describes the development of pathway-centered mechanistic synthesis across DNA and RNA virus families and further integrate innate immune antagonism, endoplasmic reticulum stress, antigen-presentation competence, cross-presentation limits, and virus-shaped peptide landscapes into a unified framework for understanding viral control of MHC-I output and its translational implications.
Abstract
Abstract Viral immune evasion of the major histocompatibility complex class I (MHC-I) antigen processing and presentation (APP) pathway is a centerpiece of the art of deception that enables persistence, reinfection, and severe disease. It does so by blunting peptide-MHC-I (pMHC-I) display, weakening CD8+ cytotoxic T lymphocyte (CTL) surveillance, and balancing the counterpressure imposed by natural killer (NK) cell missing-self responses. Rather than relying on a single trick, viruses deploy coordinated, multinode interference that functionally rewires the APP assembly line. These deceptive strategies include limiting antigen substrate availability, reshaping proteasomal peptide generation, sabotaging transporters associated with antigen processing (TAP)-dependent peptide import, disrupting peptide-loading complex-assisted editing, misdirecting MHC-I trafficking, and accelerating surface pMHC-I degradation. In parallel, many viruses fine-tune immune visibility through allele-selective modulation and nonclassical MHC circuits such as human leukocyte antigen E (HLA-E), thereby optimizing CTL evasion without inducing overwhelming NK activation. This review, therefore, describes the development of pathway-centered mechanistic synthesis across DNA and RNA virus families. We further integrate innate immune antagonism, endoplasmic reticulum stress, antigen-presentation competence, cross-presentation limits, and virus-shaped peptide landscapes into a unified framework for understanding viral control of MHC-I output and its translational implications.
HLA-Shuttle restores antigen presentation in immunologically cold tumor cells, facilitating identification of TAAs with favorable therapeutic potential and identifying multiple novel tumor associated antigens (TAAs) from both known and novel cancer immunotherapy targets.
Daniel Hwang, Molly C. Erdman, Santosh Adhikari et al.· Journal of Immunology· 0 citations
Understanding how CSFV manipulates antigen-presentation pathways provides crucial insights for the design of next-generation vaccines and therapeutic strategies capable of restoring robust antiviral immunity.
Nagarajan Siddharthan, M. Vijay, M. Roopa et al.· Asian Pacific Journal of Tro...· 0 citations
Through regulation of MHC I gene expression, PA-X decreases the rate of MHC I trafficking during infection, allowing the virus to replicate and spread, particularly in hosts with prior immunity to influenza A virus, and contributing to the continued success of this virus.
Alessandra C. Setaro, M. Gaglia· Journal of Immunology· 0 citations
The main mechanisms of antigen acquisition, endocytic/lysosomal factors controlling MHCII-restricted processing and presentation, and evidence linking lysosomal dysfunction to autoimmunity are explored.
Gabriele Sergio Colangelo, Kyra J Cowan, Federico Riccardi Sirtori et al.· Journal of Immunology· 0 citations
3 vaccine design principles are concluded: prioritize epitopes where substitutions carry measurable fitness costs, avoid immunogens dominated by mutable targets, and account for antigen presentation context and inhibitory NK signaling when evaluating epitope choice.
Simon Mallal, Amir Asiaee· Pathogens and Immunity· 3 citations
The biology, disease-associated functions, and therapeutic targeting of nonclassical MHC-I molecules are synthesized, integrating immune checkpoint blockade, antibody-based therapeutics, and MR1- and CD1-restricted cellular immunotherapies into a unified framework.